Tuesday, 7 July 2015
We have been working with the Cambridge Judge Business School to nurture life science entrepreneurship in Cambridge. The ‘Accelerate Cambridge’ Life Sciences programme aims to identify, train and mentor early-stage life science ventures. The 54-hour startup weekend was hard work but also a great learning experience for the budding science entrepreneurs – and for their AstraZeneca and MedImmune mentors. Read more on the Judge Business School’s Accelerate Cambridge Blog.
This collaboration is one of several that AstraZeneca and our global biologics research and development arm, MedImmune, have with the University of Cambridge. Most recently, we announced three new joint schemes to support more than 80 PhD scholarships and eight clinical lectureships over the next five years spanning translational science, basic and clinical research.
Previous strategic partnership between AstraZeneca, MedImmune and the University of Cambridge, which includes a substantial oncology research programme and co-location of AstraZeneca scientists at the Cancer Research UK Cambridge Institute, the largest single facility conducting cancer research in the University of Cambridge.
All of these programmes reflect our long term commitment to the science base in the UK and the shared dedication of AstraZeneca and the University of Cambridge to developing the next generation of world-class scientists.
AstraZeneca is also in the process of relocating one of our three global research and development centres and our global headquarters to Cambridge by 2016, where MedImmune’s biologics research laboratories have already been established for 25 years. Our new, purpose-built facility will be located on the Cambridge Biomedical Campus and house approximately 2,000 employees, many of whom have already relocated to interim research and office facilities in Cambridge.